Indication
Primary Plasma Cell Leukemia
3 clinical trials
6 products
6 drugs
Product
CT071Clinical trial
A Phase 1/2 Open Label Study to Evaluate the Safety and Efficacy of CT071, an Autologous Anti-GPRC5D CAR T, in Relapsed/Refractory Multiple Myeloma (RRMM) or Relapsed/Refractory Primary Plasma Cell Leukemia (RRpPCL)Status: Not yet recruiting, Estimated PCD: 2027-06-15
Clinical trial
Clinical Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-20
Product
DaratumumabDrug
CarfilzomibProduct
LenalidomideProduct
DexamethasoneDrug
CisplatinDrug
epirubicinDrug
cyclophosphamideProduct
EtoposideDrug
MelphalanDrug
bortezomibClinical trial
A Clinical Trial to Explore the Safety and Efficacy of CT071 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell LeukemiaStatus: Recruiting, Estimated PCD: 2024-11-30
Product
CAR-T cells